Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
101.40    -1.80 (-1.74%)
Bid:
101.40
Ask:
102.20
Spread: 0.80 (0.789%)
Market Cap: £166.24m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

17 May 2012 07:00

RNS Number : 5270D
Yule Catto & Co PLC
17 May 2012
 



 17 May 2012

 

Yule Catto & Co plc (the "Group") 

 

AGM & Interim Management Statement

 

At this morning's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter Wood will make the following statement which also comprises the Group's interim management statement for the period 1 January 2012 to date.

 

Profitability for the period was substantially ahead of prior year* and in line with the Board's expectations, in what has been a very challenging environment. The economic issues, particularly in Europe, have produced an environment of high raw material volatility and a general lack of business confidence.

 

In our Europe and North America segment, volumes in Q1 were 11% below what was a strong start to 2011, but 14% ahead of Q4 2011. Weakness was most evident in sales to the construction sector. Margin management has more than compensated for the lower volume levels, and together with the benefit of the planned synergies, the segment operating profit was substantially ahead of prior year.

 

In our Asia and ROW segment, the Construction and Coatings business unit showed good year on year improvement. However, in Health and Protection, demand remained subdued. Asia and ROW volumes were down 1% on Q1 2011 and 11 % ahead of Q4 2011. Margins in Health and Protection in the first half of 2011 were reasonably strong and have not been maintained at these high levels. Consequently results overall for the segment were below prior year.

 

Synergies hit an annualised run rate of £20 million as at the end of Marchand remain on track for £25M at the end of Q1 next year. This represents a £15M full year synergy benefit to 2012 operating profits compared to prior year.

 

The Group's latex expansion in Malaysia remains on track for production in the fourth quarter. This expansion will allow us to keep pace with long term demand in the high growth nitrile latex market and allow additional growth through the sale of locally manufactured SBR.

 

Net debt at the end of April was £171M, slightly up on the year end position of £164M

 

The Board also notes the current weakness of the euro which has hit 1.25 against sterling in recent days, having averaged 1.20 over the first four months of 2012, and 1.15 through 2011. The Group made a little over half of its operating profit in the euro zone in 2011. The translation effect of a one cent movement in the euro equates to approximately £0.5M of operating profit.

 

The environment remains both challenging and volatile. Against this background, the Board is pleased with the Group's financial performance year to date, and its expectations for the performance of the Group over the remainder of the year remain unchanged.

 

Note: * The Group reported an underlying proforma PBT of £96.0M for full year 2011, which included an adjustment to reflect the first quarter's pre acquisition operating profit of PolymerLatex of £13.3M and an estimated interest cost of £2.1M. Comments on PBT, operating profit performance and volumes for the period under review compared to 2011 are based on this proforma basis.

 

- Ends -

 

ENQUIRIES:

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

 

David Blackwood, Group Finance Director

 

 

 

 

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

 

John Olsen

 

Ian Payne

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLFFELEVIRLIF
Date   Source Headline
4th Sep 20203:15 pmRNSDirector Declaration
6th Aug 20207:00 amRNSInterim Results for six months ended 30 June 2020
27th Jul 202010:00 amRNSPost Stabilisation Notice
16th Jul 20207:00 amRNSAppointment of Non-Executive Director
8th Jul 20204:16 pmRNSHolding(s) in Company
8th Jul 20204:14 pmRNSHolding(s) in Company
19th Jun 20207:00 amRNSSynthomer announces the pricing of senior notes
16th Jun 202011:54 amRNSPre Stabilisation Notice
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding
30th Jul 201912:59 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:55 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.